|
Dear Colleagues,
Demand for nirsevimab (Beyfortus®), the monoclonal antibody injection to protect infants from RSV, has been high this season and there is limited availability nationally. Like many others throughout the United States, Children’s Healthcare of Atlanta has a limited supply of nirsevimab. Based on guidance from CDC, Children’s is prioritizing our limited supply of nirsevimab to infants and children who are hospitalized at Children’s or who are established Children’s outpatients currently receiving care for complex medical conditions. We are unable to accept appointments to provide nirsevimab outside of these settings.
We understand that this has been a notable RSV season to date and we share the goal of wanting to protect all infants and children from severe illness. We anticipate that supplies of nirsevimab for children weighing 5 kilograms or more will remain limited for the rest of the 2023-2024 RSV season and hope for wider availability for next year.
Please encourage the pregnant parents of children in your practice to receive an RSV vaccine between 32-36 weeks of gestation to protect them and their neonates against RSV disease.
We will continue to provide updates via email and our physician newsletters. As always, thank you for all the ways you care for kids in our communities.
Sincerely,
Jim Fortenberry, MD, MCCM,
FAAP, FELSO
Chief Medical Officer
Andi L. Shane, MD, MPH, MSc
Division Chief, Infectious Diseases
|